Author:
White Joleen T.,Argento Martell Lisa,Prince William S.,Boyer Ryan,Crockett Lucy,Cox Christopher,Van Tuyl Andrea,Aguilera Allora,Foehr Erik
Publisher
Springer Science and Business Media LLC
Reference20 articles.
1. N. Casadevall, J. Nataf, B. Viron, A. Kolta, J. J. Kiladjian, P. Martin-Dupont, P. Michaud, T. Papo, V. Ugo, I. Teyssandier, B. Varet, and P. Mayeux. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N. Engl. J. Med. 346:469–475 (2002).
2. H. P. Hartung, C. Polman, A. Bertolotto, F. Deisenhammer, G. Giovannoni, E. Havrdova, B. Hemmer, J. Hillert, L. Kappos, B. Kieseier, J. Killestein, C. Malcus, M. Comabella, A. Pachner, H. Schellekens, F. Sellebjerg, K. Selmaj, and P. S. Sorensen. Neutralising antibodies to interferon beta in multiple sclerosis: expert panel report. J. Neurol. 254:827–837 (2007).
3. G. L. Bray, E. D. Gomperts, S. Courter, R. Gruppo, E. M. Gordon, M. Manco-Johnson, A. Shapiro, E. Scheibel, G. White III, and M. Lee. A multicenter study of recombinant factor VIII (recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. The Recombinate Study Group. Blood. 83:2428–2435 (1994).
4. P. S. Kishnani, D. Corzo, M. Nicolino, B. Byrne, H. Mandel, W. L. Hwu, N. Leslie, J. Levine, C. Spencer, M. McDonald, J. Li, J. Dumontier, M. Halberthal, Y. H. Chien, R. Hopkin, S. Vijayaraghavan, D. Gruskin, D. Bartholomew, P. A. van der, J. P. Clancy, R. Parini, G. Morin, M. Beck, G. S. De la Gastine, M. Jokic, B. Thurberg, S. Richards, D. Bali, M. Davison, M. A. Worden, Y. T. Chen, and J. E. Wraith. Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease. Neurology. 68:99–109 (2007).
5. E. Koren, L. A. Zuckerman, and A. R. Mire-Sluis. Immune responses to therapeutic proteins in humans—clinical significance, assessment and prediction. Curr. Pharm. Biotechnol. 3:349–360 (2002).
Cited by
12 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献